|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 静脉血栓栓塞症的抗血栓治疗:美国《胸科学》杂志指南显示文摘包括深静脉血栓和肺栓塞在内的静脉血栓栓塞症是癌症患者的主要并发症,发生率为4%~20%,并且是常见的潜在致命性急症。本文介绍了美国《胸科学》杂志指南中VET的抗血栓治疗的部分内容,其以第9版《美国胸内科医师学会循证临床实践指南》中的《静脉血栓栓塞症的抗血栓治疗:抗血栓治疗和阻止血栓形成》一文为参照,基于静脉血栓栓塞症治疗的Ⅲ期试验的发表年份,对口服抗凝剂(达比加群、利伐沙班、阿哌沙班、依度沙班)进行先后阐述(但是这一排序并不是指南专家组对药剂的优劣排序),以为临床医生提供参考。 | Kearon C Akl EA Ornelas J Blaivas A Jimenez D Bounameaux H Huisman M King CS MorrisT Sood N Stevens SM Vintch JRE Wells P Woller SC Moores CL 本刊编辑部 | 2016 | 中国全科医学2016，19，9： | 10 |
| 2 | Dyslipidemia management in primary prevention of cardiovascular disease:Current guidelines and strategies显示文摘Cardiovascular disease is the leading cause of death in the United States. In 2010, the Centers for Disease Control and Prevention estimated that $444 billion was spent on cardiovascular diseases alone, about $1 of every $6 spent on health care. As life expectancy continues to increase, this annual cost will also increase, making costeffective primary prevention of cardiovascular disease highly desirable. Because of its role in development of atherosclerosis and clinical events, dyslipidemia management is a high priority in cardiovascular prevention. Multiple major dyslipidemia guidelines have been published around the world recently, four of them by independent organizations in the United States alone. They share the goal of providing clinical guidance on optimal dyslipidemia management, but guidelines differ in their emphasis on pharmacotherapy, stratification of groups, emphasis on lifestyle modification, and use of a fixed target or percentage reduction in low density lipoprotein cholesterol. This review summarizes eight major guidelines for dyslipidemia management and considers the basis for their recommendations. Our primary aim is to enhance understanding of dyslipidemia management guidelines in patient care for primary prevention of future cardiovascular risk. | Aditya D Hendrani Tolulope Adesiyun Renato Quispe Steven R Jones Neil J Stone Roger S Blumenthal Seth S Martin | 2016 | World Journal of Cardiology2016，8，2： | 5 |
| 3 | Evaluating the accuracy of American Society for Gastrointestinal Endoscopy guidelines in patients with acute gallstone pancreatitis with choledocholithiasis显示文摘BACKGROUND Acute gallstone pancreatitis(AGP) is the most common cause of acute pancreatitis(AP) in the United States. Patients with AGP may also present with choledocholithiasis. In 2010, the American Society for Gastrointestinal Endoscopy(ASGE) suggested a management algorithm based on probability for choledocholithiasis, recommending additional imaging for patients at intermediate risk and endoscopic retrograde cholangiopancreatography(ERCP) for patients at high risk of choledocholithiasis. In 2019, the ASGE guidelines were updated using more specific criteria to categorize individuals at high risk for choledocholithiasis. Neither ASGE guideline has been studied in AGP to determine the probability of having choledocholithiasis.AIM To determine compliance with ASGE guidelines, assess outcomes, and compare 2019 vs 2010 ASGE criteria for suspected choledocholithiasis in AGP.METHODS We conducted a retrospective cohort study of 882 patients admitted with AP to a single tertiary care center from 2008-2018. AP was diagnosed using revised Atlanta criteria and AGP was defined as the presence of gallstones on imaging or with cholestatic pattern of liver injury in the absence of another cause. Patients with chronic pancreatitis and pancreatic malignancy were excluded as were those who went directly to cholecystectomy prior to assessment for choledocholithiasis. Patients were assigned low, intermediate or high risk based on ASGE guidelines. Our primary outcomes of interest were the proportion of patients in the intermediate risk group undergoing magnetic resonance cholangiopancreatography(MRCP) first and the proportion of patients in the high risk group undergoing ERCP directly without preceding imaging. Secondary outcomes of interest included outcome differences based on if guidelines were not adhered to. We then evaluated the diagnostic accuracy of 2019 in comparison to the 2010 ASGE criteria for patients with suspected choledocholithiasis. We performed the t test or Wilcoxon rank sum test, as appropriate, to analyze if there were outcome differences based on if guidelines were not adhered to. Kappa coefficients were calculated to measure the degree of agreement between pairs of variables.RESULTS In this cohort, we identified 235 patients with AGP of which 79 patients were excluded as they went directly to surgery for cholecystectomy without prior MRCP or ERCP. Of the remaining 156 patients, 79 patients were categorized as intermediate risk and 77 patients were high risk for choledocholithiasis according to the 2010 ASGE guidelines. Among 79 intermediate risk patients, 54(68%) underwent MRCP first whereas 25 patients(32%) went directly to ERCP. For the 54 patients with intermediate risk who had MRCP first, 36 patients had no choledocholithiasis while 18 patients had evidence of choledocholithiasis prompting ERCP. Of these patients, ERCP confirmed stone disease in 11 patients. Of the 25 intermediate risk patients who directly underwent ERCP, 18 patients had stone disease. One patient with a normal ERCP developed post ERCP pancreatitis. Patients undergoing MRCP in this group had a significantly longer length of stay(5.0 vs 4.0 d, P = 0.02). In the high risk group, 64 patients(83%) had ERCP without preceding imaging, of which, 53 patients had findings consistent with choledocholithiasis, of which 13 patients(17%) underwent MRCP before ERCP, all of which showed evidence of stone disease. Furthermore, all of these patients ultimately had an ERCP, of which 8 patients had evidence of stones and 5 had normal examination.RESULTS Our cohort also demonstrated that 58% of all 156 patients with AGP had confirmed choledocholithiasis(79% of the high risk group and 37% of the intermediate group when risk was assigned based on the 2010 ASGE guidelines). When the updated 2019 ASGE guidelines were applied instead of the original 2010 guidelines, there was moderate agreement between the 2010 and 2019 guidelines(kappa = 0.46, 95%CI: 0.34-0.58). Forty-two of 77 patients were still deemed to be high risk and 35 patients were downgraded to intermediate risk. Thirty-five patients who were originally assigned high risk were reclassified as intermediate risk. For these 35 patients, 26 patients had ERCP findings consistent with choledocholithiasis and 9 patients had a normal examination. Based on the 2019 criteria, 9/35 patients who were downgraded to intermediate risk had an unnecessary ERCP with normal findings(without a preceding MRCP).CONCLUSION Two-thirds in intermediate risk and 83% in high risk group followed ASGE guidelines for choledocholithiasis. One intermediate-group patient with normal ERCP had post-ERCP AP, highlighting the risk of unnecessary procedures. | Supisara Tintara Ishani Shah William Yakah Awais Ahmed Cristina S Sorrento Cinthana Kandasamy Steven D Freedman Darshan J Kothari Sunil G Sheth | 2022 | World Journal of Gastroenterology2022，28，16： | 3 |
| 4 | Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea 显示文摘 | McCullough M J Clemons K V Stevens D A | 1999 | J Clin Microbiol1999，37，2： | 2 |
| 5 | Intercalibration of vegetation indices from different sensor systems显示文摘 | Michael D Steven Timothy J Malthus Frédéric Baret Hui Xu Mark J Chopping | 2003 | Remote Sensing of Environment2003，，4： | 2 |
| 6 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study显示文摘 | Pierre Fenaux Ghulam J Mufti Eva Hellstrom-Lindberg Valeria Santini Carlo Finelli Aristoteles Giagounidis Robert Schoch Norbert Gattermann Guillermo Sanz Alan List Steven D Gore John F Seymour John M Bennett John Byrd Jay Backstrom Linda Zimmerman David M | 2009 | Lancet Oncology2009，，： | 2 |
| 7 | Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry显示文摘AIM: To investigate the survival of individuals with colorectal cancer (CRC) with inflammatory bowel disease (IBD-associated CRC) compared to that of individuals without IBD diagnosed with CRC. METHODS: Epidemiologic, clinical, and follow-up data were obtained from the Colon Cancer Family Registry (Colon CFR). IBD-associated cases were identified from self-report of physician diagnosis. For a subset of participants, medical records were examined to confirm self-report of IBD. Cox proportional hazards regression was applied to estimate adjusted hazard ratios (aHR) and 95%CI of mortality, comparing IBD-associated to non-IBD-associated CRC, adjusted for age at CRC diagnosis, sex, Colon CFR phase, and number of prior endoscopies. Following imputation to complete CRC stage information, adjustment for CRC stage was examined. RESULTS: A total of 7202 CRC cases, including 250 cases of IBD-associated CRC, were analyzed. Over a twelve year follow-up period following CRC diagnosis, 2013 and 74 deaths occurred among non-IBD associated CRC and IBD-associated CRC patients, respectively. The difference in survival between IBD-associated and non-IBD CRC cases was not statistically significant (aHR = 1.08; 95%CI: 0.85-1.36). However, the assumption of proportional hazards necessary for valid inference from Cox regression was not met over the entire follow-up period, and we therefore limited analyses to within five years after CRC diagnosis when the assumption of proportional hazards was met. Over this period, there was evidence of worse prognosis for IBD-associated CRC (aHR = 1.36; 95%CI: 1.05-1.76). Results were similar when adjusted for CRC stage, or restricted to IBD confirmed in medical records. CONCLUSION: These results support the hypothesis that IBD-associated CRC has a worse prognosis than non-IBD-associated CRC. | Scott V Adams Dennis J Ahnen John A Baron Peter T Campbell Steven Gallinger William M Grady Loic LeMarchand Noralane M Lindor John D Potter Polly A Newcomb | 2013 | World Journal of Gastroenterology2013，19，21： | 2 |
| 8 | Reoperation for prosthetic aortic valve obstruction in the era of echocardiography: trends in diagnostic testing and comparison with surgical findings显示文摘 | Steven E Girard Fletcher A Miller Thomas A Orszulak Charles J Mullany Samantha Montgomery William D Edwards Henry D Tazelaar Joseph F Malouf A.Jamil Tajik | 2001 | Journal of the American College of Cardiology2001，，2： | 2 |
| 9 | Pancreatic cancer显示文摘 | Theresa Pluth Yeo Ralph H Hruban Steven D Leach Robb E Wilentz Taylor A Sohn Scott E Kern Christine A Iacobuzio-Donahue Anirban Maitra Michael Goggins Marcia I Canto Ross A Abrams Daniel Laheru Elizabeth M Jaffee Manuel Hidalgo Charles J Yeo | 2002 | Current Problems in Cancer2002，，4： | 2 |
| 10 | Adipocyte iron regulates adiponectin and insulin sensitivity显示文摘 | Gabrielsen J Scott Gao Yan Simcox Judith A Huang Jingyu Thorup David Jones Deborah Cooksey Robert C Gabrielsen David Adams Ted D Hunt Steven C Hopkins Paul N Cefalu William T McClain Donald A | 2012 | EN2012，，10： | 2 |
| 11 | Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias显示文摘 | Steven L Higgins John D Hummel Imran K Niazi Michael C Giudici Seth J Worley Leslie A Saxon John P Boehmer Michael B Higginbotham Teresa De Marco Elyse Foster Patrick G Yong | 2003 | Journal of the American College of Cardiology2003，，8： | 2 |
| 12 | Epidermal growth factor receptor inhibits colitis-associated cancer in mice显示文摘 | Dubé Philip E Yan Fang Punit Shivesh Girish Nandini McElroy Steven J Washington M Kay Polk D Brent | 2012 | EN2012，，8： | 2 |
| 13 | Complete genomes of two clinical Staphylococcus aureus strains:evidence for the rapid evolution of virulence and drug resistance显示文摘 | Holden MT Feil EJ Lindsay JA Peacock SJ Day NP Enright MC Foster TJ Moore CE Hurst L Atkin R Barron A Bason N Bentley SD Chillingworth C Chillingworth T Churcher C Clark L Corton C Cronin A Doggett J Dowd L Feltwell T Hance Z Harris B Hauser H Holroyd S Jagels K James KD Lennard N Line A Mayes R Moule S Mungall K Ormond D Quail MA Rabbinowitsch E Rutherford K Sanders M Sharp S Simmonds M Stevens K Whitehead S Barrell BG Spratt BG Parkhill J | 2004 | Proc Natl Acad Sci USA2004，101，26： | 1 |
| 14 | Bt toxin resistance from loss of a putative carbohydrate-modifying enzyme显示文摘 | Griflitts J S Whitacre J L Stevens D E | 2001 | Science2001，293，5531： | 1 |
| 15 | Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis显示文摘 | Clemons K V Lutz J E Stevens D A | 2001 | Microbes Infect2001，3，： | 1 |
| 16 | Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections 显示文摘 | Weigeh J Itani K Stevens D | 2005 | Antimicrob Agents Chemother2005，49，： | 1 |
| 17 | Properties of skeletal muscle mitochondria isolated from subsarcolemmal and intermyofibrillar regions 显示文摘 | Cogswell A M Stevens R J Hood D A | 1993 | American Journal Physiology-Cell Physiology1993，264，： | 1 |
| 18 | Effect of Long-term with Reclaimed Water on Soils of the Northern Adelaide Plains,South Australian显示文摘 | STEVENS D P MCLAUGHLIN M J SMART M K | 2003 | Australian Journal of Soil Research2003，41，5： | 1 |
| 19 | 2006, Air pollution removal by urban trees and shrubs in the United States 显示文摘 | NOWAK D J CRANE D E STEVENS J C | 2006 | Urban Forestry and Urban Greening2006，4，34： | 1 |
| 20 | Evaluation of over 100 scanner-years of computed tomography daily quality control data显示文摘 | NUTE J L RONG J STEVENS D M | 2013 | Med Phys2013，40，05： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员